{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001100.3:c.158C>A",
          "cDNA Change": {
            "transcript": "NM_001100.3",
            "ref": "C",
            "alt": "A",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutation in SNCA leads to alpha-synuclein aggregation and is a known cause of Parkinson's disease."
        }
      ]
    },
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_181517.2:c.6058G>A",
          "cDNA Change": {
            "transcript": "NM_181517.2",
            "ref": "G",
            "alt": "A",
            "position": "6058"
          },
          "Protein Change": {
            "ref": "G",
            "alt": "S",
            "position": "2019"
          },
          "Description in input context": "G2019S mutation in LRRK2 is associated with increased kinase activity and is a common cause of Parkinson's disease."
        }
      ]
    },
    {
      "Gene": "DJ-1",
      "variants": [
        {
          "HGVS": "NM_004295.2:c.497T>C",
          "cDNA Change": {
            "transcript": "NM_004295.2",
            "ref": "T",
            "alt": "C",
            "position": "497"
          },
          "Protein Change": {
            "ref": "L",
            "alt": "P",
            "position": "166"
          },
          "Description in input context": "L166P mutation in DJ-1 leads to loss of antioxidant function and is linked to Parkinson's disease."
        }
      ]
    },
    {
      "Gene": "PARK2",
      "variants": [
        {
          "HGVS": "NM_000302.3:c.356G>A",
          "cDNA Change": {
            "transcript": "NM_000302.3",
            "ref": "G",
            "alt": "A",
            "position": "356"
          },
          "Protein Change": {
            "ref": "R",
            "alt": "X",
            "position": "119"
          },
          "Description in input context": "R119X mutation in PARK2 causes loss of ubiquitin ligase activity and is associated with Parkinson's disease."
        }
      ]
    },
    {
      "Gene": "ATP13A2",
      "variants": [
        {
          "HGVS": "NM_001013433.1:c.844G>A",
          "cDNA Change": {
            "transcript": "NM_001013433.1",
            "ref": "G",
            "alt": "A",
            "position": "844"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "282"
          },
          "Description in input context": "E282K mutation in ATP13A2 is linked to reduced lysosomal function and Parkinson's disease."
        }
      ]
    }
  ],
  "Described Disease": {
    "disease_name": "Parkinson's disease",
    "mondo_id": "MONDO:0005278"
  },
  "Experiment Method": [
    {
      "assay_type": "Western blot",
      "materials_used": "SH-SY5Y cells overexpressing mutant SNCA (A53T), wild-type SH-SY5Y cells as control",
      "readout_type": "Quantitative",
      "result_description": [
        {
          "variant": "NM_001100.3:c.158C>A",
          "conclusion": "Increased alpha-synuclein aggregation",
          "molecular_effect": "Enhanced protein aggregation and fibril formation",
          "result_details": "Western blot analysis showed a 2.5-fold increase in insoluble alpha-synuclein in A53T-expressing cells compared to wild-type."
        }
      ],
      "replicates": {
        "biological": 3,
        "technical": 3
      },
      "controls": {
        "positive": "Wild-type SH-SY5Y cells",
        "negative": "Empty vector-transfected SH-SY5Y cells"
      },
      "statistical_analysis": "ANOVA with post-hoc Tukey's test (p < 0.01)",
      "thresholds": {
        "normal": "Alpha-synuclein levels within 1.5x of wild-type",
        "abnormal": "Aggregation levels exceeding 2x wild-type"
      },
      "approved_assay": "Yes"
    },
    {
      "assay_type": "Kinase activity assay",
      "materials_used": "Purified recombinant LRRK2 (G2019S mutant), wild-type LRRK2, ATP, kinase substrate",
      "readout_type": "Quantitative",
      "result_description": [
        {
          "variant": "NM_181517.2:c.6058G>A",
          "conclusion": "Increased kinase activity",
          "molecular_effect": "Enhanced phosphorylation of substrates (e.g., Rab10)",
          "result_details": "G2019S mutant showed 1.8-fold higher kinase activity compared to wild-type LRRK2 (p < 0.05)."
        }
      ],
      "replicates": {
        "biological": 3,
        "technical": 3
      },
      "controls": {
        "positive": "Wild-type LRRK2",
        "negative": "Inhibitor-treated LRRK2"
      },
      "statistical_analysis": "t-test (p < 0.05)",
      "thresholds": {
        "normal": "Kinase activity within 1.2x of wild-type",
        "abnormal": "Activity exceeding 1.5x wild-type"
      },
      "approved_assay": "Yes"
    },
    {
      "assay_type": "Mitochondrial respiration assay",
      "materials_used": "DJ-1 knockout (L166P) HEK293 cells, wild-type HEK293 cells",
      "readout_type": "Quantitative",
      "result_description": [
        {
          "variant": "NM_004295.2:c.497T>C",
          "conclusion": "Reduced mitochondrial respiration",
          "molecular_effect": "Impaired complex I function",
          "result_details": "DJ-1 L166P cells exhibited a 30% decrease in oxygen consumption rate (OCR) compared to wild-type (p < 0.01)."
        }
      ],
      "replicates": {
        "biological": 3,
        "technical": 3
      },
      "controls": {
        "positive": "Wild-type HEK293 cells",
        "negative": "DJ-1 knockout cells"
      },
      "statistical_analysis": "ANOVA with post-hoc Dunnett's test (p < 0.01)",
      "thresholds": {
        "normal": "OCR within 10% of wild-type",
        "abnormal": "OCR reduction exceeding 20%"
      },
      "approved_assay": "Yes"
    },
    {
      "assay_type": "Immunohistochemistry",
      "materials_used": "Postmortem brain tissue from PARK2 R119X carriers, age-matched controls",
      "readout_type": "Qualitative",
      "result_description": [
        {
          "variant": "NM_000302.3:c.356G>A",
          "conclusion": "Loss of ubiquitin-positive inclusions",
          "molecular_effect": "Reduced proteasome activity",
          "result_details": "PARK2 R119X brains showed 50% fewer ubiquitin-positive inclusions compared to controls (p < 0.05)."
        }
      ],
      "replicates": {
        "biological": 3,
        "technical": 2
      },
      "controls": {
        "positive": "Age-matched non-carrier controls",
        "negative": "PARK2 knockout mice"
      },
      "statistical_analysis": "Chi-square test (p < 0.05)",
      "thresholds": {
        "normal": "Ubiquitin-positive inclusions in >75% of neurons",
        "abnormal": "Inclusions in <50% of neurons"
      },
      "approved_assay": "Yes"
    },
    {
      "assay_type": "Cell viability assay",
      "materials_used": "ATP13A2 E282K HEK293 cells, wild-type HEK293 cells",
      "readout_type": "Quantitative",
      "result_description": [
        {
          "variant": "NM_001013433.1:c.844G>A",
          "conclusion": "Reduced cell viability",
          "molecular_effect": "Increased lysosomal membrane permeability",
          "result_details": "E282K cells exhibited 25% lower viability compared to wild-type (p < 0.01)."
        }
      ],
      "replicates": {
        "biological": 3,
        "technical": 3
      },
      "controls": {
        "positive": "Wild-type HEK293 cells",
        "negative": "ATP13A2 knockout cells"
      },
      "statistical_analysis": "t-test (p < 0.05)",
      "thresholds": {
        "normal": "Viability >85% of wild-type",
        "abnormal": "Viability <75% of wild-type"
      },
      "approved_assay": "Yes"
    }
  ]
}